The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

News Headlines and Feed

Business News Videos

Aerocrine signs distribution agreement with third largest Chinese pharmaceutical company

Tuesday, 25 September 2012
Aerocrine AB (OMX Nordic Exchange: AERO) today announces the signing of an import and distribution agreement with Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) for Aerocrine’s products for the Chinese market. SPH is the third largest pharmaceutical company in China, with an extensive network of local sales people across China.

The agreement, effective as of September 24, 2012, gives SPH exclusive rights for import and non-exclusive rights for distribution of Aerocrine’s instrument NIOX MINO® and test kits, used for diagnosing and monitoring patients with asthma, on the Chinese market, the company said in a press release.

Aerocrine’s product, NIOX MINO® is approved by the Chinese authorities for commercialization. The FeNO method is mentioned in the clinical guidelines for asthma in China and has been approved for PPT (Pay Per Test) in 15 of the 32 provinces in China, which means that the doctors are allowed to charge patients for the tests.
“It is very rare that you come across a product that is so beneficial in so many aspects. As a pediatrician I have seen how many patients have uncontrolled asthma and now when using Aerocrine's product, they become better diagnosed and better medicated and improve their quality of life. In the end all of these patients will have positive economic effects for the health care sector as well as the country, so we are proud to be representing Aerocrine”, says Mr Yu Qingliu, General Manager Medical Device & Surgicals of Shanghai Pharmaceutical Holding, according to the press release.

Asthma is a chronic inflammatory disease of the airways characterized by symptoms including cough, wheezing and difficulty in breathing. Asthma is one of this world’s most common and costly diseases, affecting 8-10 % of the world population and always in the top five in terms of costs of chronic diseases.

Asthma is very often linked to allergic rhinitis: 80% of allergic asthma sufferers also have allergic rhinitis and 40% of patients with untreated rhinitis go on to develop asthma.
By Scancomark.com Team; News source: Press release from the company

We welcome your contribution. Did you find anything wrong with this article? Do you want to contribute to our news network? Do have a news tip or assist us with a correction